IDEAYA Biosciences, Inc. Proceeds from Sale of Debt Securities, Available-for-sale
IDEAYA Biosciences, Inc. (IDYA) reported Proceeds from Sale of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-20.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2024-02-20
- IDEAYA Biosciences, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $0.00.
- IDEAYA Biosciences, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- IDEAYA Biosciences, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2021 was $4.02M.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-20 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-20 |
| 2021-12-31 | $4.02M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |